Early pharmacological treatment of acute heart failure syndromes: A systematic review of clinical trials

Acute Cardiac Care

Volumn 9, Issue 1, 2007, Pages 10-21

  De Luca, Leonardo ^a   Fonarow, Gregg C ^b   Mebazaa, Alexandre ^c   Shin, David D ^f   Collins, Sean P ^d   Swedberg, Karl ^e   Gheorghiade, Mihai ^f,g  

^a EUROPEAN HOSPITAL   (Italy)

^b UCLA MEDICAL CENTER   (United States)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f NORTHWESTERN UNIVERSITY   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute heart failure; Blood pressure; Classification; Epidemiology; Prognostic factors; Treatment; Trials

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ATRIAL NATRIURETIC FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; ISTAROXIME; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; PLACEBO; PST 2744; TEZOSENTAN; TOLVAPTAN; UNCLASSIFIED DRUG; URODILATIN; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; BLOOD PRESSURE MONITORING; BODY WEIGHT; CLINICAL TRIAL; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EMBASE; HEALTH SURVEY; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART MUSCLE INJURY; HEART OUTPUT; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TACHYPHYLAXIS;

CARDIAC OUTPUT, LOW; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; HUMANS; PROGNOSIS; SYNDROME;

EID: 34247181132     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940601134487     Document Type: Review

References (89)

1. Gheorghiade M, Zannad F, Sopko G, et al. International Working Group on Acute Heart Failure Syndromes. International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958-68.
2. Adams KF Jr, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry(ADHERE). Am Heart J. 2005;149:209-16.
3. Cleland JG, Swedberg K, Follath F, et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euro Heart Failure survey Programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442-63.
4. Gheorghiade M, Abraham W, Albert N, Greenberg B, O'Connor C, She L, Stough W, Yancy C, Young J, Fonarow G. for the OPTIMIZE-HF Investigators and Coordinators. Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure. JAMA. 2006;296:2217-2226.
5. Nieminen MS, Bohm M, Cowie MR, et al. ESC Committee for Practice Guideline. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
6. Guidelines Writing Committee. HFSA 2006 Comprehensive Heart Failure Practice Guidelines. J Card Fail. 2006;12:e1-e122.
7. Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS, for the American College of Emergency Physicians Clinical Policies Writing Committee. Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Heart Failure Syndromes. Ann Emerg Med. 2006; in press.
8. Collins SP, Lindsell CJ, Storrow AB, Abraham WT, ADHERE Scientific Advisory Committee, Investigators and Study Group. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med. 2006;47:13-8.
9. Komajda M, Follath F, Swedberg K, et al., Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464-74.
10. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol. 2003;41:1510-8.
11. Fonarow GC, Adams KF, for the ADHERE Investigators. Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology: analysis of 33,046 patients in the ADHERE registry. JAMA. 2005;293:572-80.
12. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004;10:460-66.
13. Tavazzi L, Maggioni AP, Lucci D, et al. on behalf of the Italian survey on Acute Heart Failure Investigators. Eur Heart J. 2006;27:1207-15.
14. Gheorghiade M, Klein L, Abraham W, et al. The Relation Between Admission Systolic Blood Pressure And Outcomes In Hospitalized Patients With Heart Failure With Reduced Or Preserved Sytolic Function: An OPTIMIZE-HF Analysis. Circulation. 2005;112(Suppl):128S.
15. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail. 2005;11:200-5.
16. McDermott MM, Feinglass J, Lee PI, et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J. 1997;134:728-36.
17. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833-8.
18. Perna ER, Macin SM, Cimbaro Canella JP, et al. Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. Int J Cardiol. 2005;99:253-61.
19. Klein L, O'Connor CM, Leimberger JD, et al. OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the OPTIME-CHF study. Circulation. 2005;111:2454-60.
20. Gheorghiade M, Hellkamp AS, Pina IL, et al. Hemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. J Am Coll Cardiol. 2005;45:145A.
21. Gheorghiade M, Adams KF, O'Connor CM, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: Insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF). J Am Coll Cardiol. 2005;45:145A.
22. Maisel A, Hollander JE, Guss D, et al. Rapid Emergency Department Heart Failure Outpatient Trial investigators. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328-33.
23. Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-7.
24. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-74.
25. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail. 2005;11:200-5.
26. McDermott MM, Feinglass J, Lee PI, et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J. 1997;134:728-36.
27. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625-8.
28. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-7.
29. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic Targets in the Early Phase of Acute Heart Failure Syndromes. Am J Cardiol. 2005;96:11G-7G.
30. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med, Suppl.4:S18-27.
31. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
32. Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response and death in acute heart failure. Am J Cardiol. 1997;80:519-23.
33. Neuberg GW, Miller AB, O'Connor CM, et al. For the PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31-8.
34. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-8.
35. Emerman CL, de Marco T, Costanzo MR, Peacock WF. Impact of intravenous diuretics on the outcome of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. J Card Fail. 2004;10:S116-S7.
36. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;2:376-82.
37. Mehra MR. Optimizing outcomes in the patient with acute decompensated heart failure. Am Heart J. 2006;151:571-79.
38. Jaski BE, Ha J, Denys BG, Lamba S, Trupp RJ, Abraham WT. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail. 2003;9:227-31.
39. Bourge RC, Tallaj JA. Ultrafiltration: a new approach toward mechanical diuresis in heart failure. J Am Coll Cardiol. 2005;46:2052-3.
40. Dahle TG, Blake D, Ali SS, Olinger CC, Bunte MC, Boyle AJ. Large volume ultrafiltration for acute decompensated heart failure using standard peripheral intravenous catheters. J Card Fail. 2006;12:349-52.
41. Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047-51.
42. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA. 2002;287:1531-40.
43. Abraham WT, Adams KF, Fonarow GC, et al. ADHERE Scientific Advisory Committee and Investigators and ADHERE Study Group. In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications: An Analysis From the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64.
44. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure. N Engl J Med. 1982;306:1129-35.
45. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-5.
46. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-91.
47. Bayram M, De Luca L, Massie BM, Gheorghiade M. Dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes: A reassessment. Am J Cardiol. 2005;96:47G-58G.
48. Felker GM, Benza RL, Chandler AB, et al. OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997-1003.
49. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol. 1989;13:134-42.
50. Gheorghiade M, St Clair J, St Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol. 1987;9:849-57.
51. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-33.
52. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006;113:2556-2564.
53. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-84.
54. Annane D, Bellissant E, Pussard E, et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation. 1996;94:1316-24.
55. Peacock WF, Hollander JE, Diercks DB. Morphine for acute decompensated heart failure: valuable adjunct or a historical remnant? Acad Emerg Med. 2005;12:S97.
56. Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA. Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema Systematic Review and Meta-analysis. JAMA. 2005;294:3124-30.
57. Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet. 2006;367:1155-63.
58. De Luca L, Colucci W, Nieminem M, Massie B, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006;27:1908-20.
59. Figgit DP, Gillies PS, Goa KL. Levosimendan. Drugs. 2001;61:613-27.
60. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
61. Zairis MN, Apostolatos C, Anastasiadis P. The Effect of a Calcium Sensitizer or an Inotrope or None in Chronic Low Output Decompensated Heart Failure: Results From the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO). J Am Coll Cardiol. 2004;43(suppl 1):206A-7A.
62. Packer M, Colucci WS, Fisher L. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. J Card Fail. 2003;9:S61.
63. Packer M. The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy-2 (REVIVE-2) trial. Late-breaking Clinical Trials. American Heart Association, Annual Scientific Session, Dallas, Tx, November 13-16, 2005.
64. Mebazaa A. The SURVival of Patients with Acute Heart Failure in Need of IntraVEnous Inotropic Support (SURVIVE) trial. Late-breaking Clinical Trials. American Heart Association, Annual Scientific Session, Dallas, Tx, November 13-16, 2005.
65. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992;85:510-7.
66. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374-9.
67. Gheorghiade M, De Luca L, Bonow RO. Neurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials. Am J Cardiol. 2005;96(suppl):3L-9L.
68. Coletta AP, Cleland JG. Clinical trials update: highlights of the Scientific Sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail. 2001;3:747-50.
69. Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Hemodynamic and clinical effects of tezosentan, and intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2003;42:140-147.
70. O'Connor CM, Gattis WA, Adams KF, et al. Randomized Intravenous TeZosentan Study-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes. J Am Coll Cardiol. 2003;41:1452-7.
71. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5 randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of Pulmonary edema. J Am Coll Cardiol. 2003;41:204-10.
72. Teerlink JR, McMurray JJV. VERITAS: Value of endothelin receptor inhibition with tezosentan in acute heart failure studies. Presented at Annual Meeting of the American College of Cardiology 2005, March 6-9, Orlando, Fl, USA.
73. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-91.
74. De Luca L, Orlandi C, Udelson JE, Fedele F, Gheorghiade M. Overview of Vasopressin Receptor Antagonists in Heart Failure Resulting in Hospitalization. Am J Cardiol. 2005;96(suppl):24L-33L.
75. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417-23.
76. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J. 2003;145:179-86.
77. Russell SD, Adams KF, Shaw JP, Gattis WA, O'Connor CM. Results of a twelve week double-blind, placebo-controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure. J Card Fail. 2003;9:S60.
78. Verbalis JG, Bisaha JG, Smith N. Novel Vasopressin V 1A and V 2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia. Circulation. 2004;110(abstr.):III723.
79. Gheorghiade M, Gattis WA, O'Connor CM, et al., Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA. 2004;291:1963-71.
80. Gheorghiade M, Konstam MA, Udelson JE, Ouyang J, Orlandi C. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients. J Am Coll Cardiol. 2002;39(abstr.):171A.
81. Gheorghiade M, Orlandi C, Burnett J, et al. for the EVEREST Study Investigators. Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Long Term Efficacy And Safety of Oral Tolvaptan in Patients Hospitalized With Worsening Heart Failure: Efficacy of Vasopressin antagonism in hEart failuRE: outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005;11:260-9.
82. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 2005;69:283-90.
83. Mitrovic V, Luss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forssmann WG, Meyer M. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005;150:1239.e1-1239.e8.
84. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823-2832.
85. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348-53.
86. + pump inhibitors with different toxicity: digoxin and PST 2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]. J Pharmacol Exp Ther. 2005;313:207-215.
87. Adamson PB, Vanoli E, Mattera GG, Germany R, Gagnol JP, Carminati P, Schwartz PJ. Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure. J Cardiovasc Pharmacol. 2003;42:169-173.
88. Sabbah HN, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M. Istaroxime: a new lusi-inotropic agent for heart failure. Am J Cardiol. 2007 (in press).
89. Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, Komajda M, Gheorghiade M. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol. 2007 (in press).